← Leaderboards
Emma E. Moore
Omeros Corporation
$823,488
Attributed
$823,488
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $676.9K · FY2008–09$1M$750K$500K$250K$0
'08
'09
Funding mix
By agency
NIH$823,488 · 3
By mechanism
R43$823,488 · 3
Top collaborators
No co-investigators on record.
Most similar at Omeros Corporation
Same institution · by research overlap
- Thomas Anton Dudler$1,052,057
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistAffectEvaluationResponseNovel TherapeuticsPathway InteractionsPersonsCollaborationsMediatingJointsGenerationsGovernmentHomeostasisGrowth FactorCattleInsulin-Like Growth Factor ICartilageChondrocytesInflammatoryAreaCytokineDegenerative PolyarthritisInterleukin-1Monitor
Grant awards (4)
A novel therapeutic target for OA that restores IGF-1 responses$334,600
R43 · FY2009 · AR · contact PI
Novel therapy for osteoporosis$193,888
R43 · FY2009 · AG · contact PI
A Novel Therapeutic Target for OA that Restores IGF-1 Responses$148,400
R43 · FY2009 · AR · contact PI
MASP-2: A Potential New Target for Treatment of Rheumatoid Arthritis$146,600
R43 · FY2008 · AR · contact PI